- cafead   Aug 01, 2024 at 12:02: PM
via Another of Ionis Pharmaceuticals’ key midphase readouts has fallen short of expectations, prompting the biotech to stop studying the Roche-partnered candidate in an advanced form of age-related macular degeneration.
article source
article source